NASDAQ:IART - Integra Lifesciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$45.86 -0.11 (-0.24 %)
(As of 01/23/2019 04:00 PM ET)
Previous Close$45.97
Today's Range$45.13 - $46.75
52-Week Range$42.14 - $67.50
Volume339,417 shs
Average Volume669,268 shs
Market Capitalization$3.91 billion
P/E Ratio23.64
Dividend YieldN/A
Beta0.93
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. The company also sells approximately 60,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, it provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, the company sells hardware products, such as bone and joint fixation, and joint replacement devices; implants; and instruments, which provide for the orthopedic reconstruction of bone in the hand, wrist, elbow, and shoulder, as well as the foot, ankle, and leg below the knee in the extremity bone and joint reconstruction procedures. Integra LifeSciences Holdings Corporation offers its products directly through various sales forces and other distribution channels in the United States, Europe, and internationally. The company was founded in 1989 and is headquartered in Plainsboro, New Jersey.

Receive IART News and Ratings via Email

Sign-up to receive the latest news and ratings for IART and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:IART
CUSIP45798520
Phone609-275-0500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.19 billion
Cash Flow$3.0431 per share
Book Value$12.26 per share

Profitability

Net Income$64.74 million

Miscellaneous

Employees4,400
Market Cap$3.91 billion
OptionableOptionable

Integra Lifesciences (NASDAQ:IART) Frequently Asked Questions

What is Integra Lifesciences' stock symbol?

Integra Lifesciences trades on the NASDAQ under the ticker symbol "IART."

When did Integra Lifesciences' stock split? How did Integra Lifesciences' stock split work?

Integra Lifesciences shares split before market open on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly minted shares were payable to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of Integra Lifesciences stock prior to the split would have 200 shares after the split.

How were Integra Lifesciences' earnings last quarter?

Integra Lifesciences Holdings Corp (NASDAQ:IART) announced its quarterly earnings data on Wednesday, October, 31st. The life sciences company reported $0.59 earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of $0.59. The life sciences company had revenue of $365.85 million for the quarter, compared to analysts' expectations of $367.89 million. Integra Lifesciences had a return on equity of 16.99% and a net margin of 5.49%. The business's revenue for the quarter was up 31.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.45 earnings per share. View Integra Lifesciences' Earnings History.

When is Integra Lifesciences' next earnings date?

Integra Lifesciences is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Integra Lifesciences.

What guidance has Integra Lifesciences issued on next quarter's earnings?

Integra Lifesciences issued an update on its FY18 earnings guidance on Wednesday, October, 31st. The company provided earnings per share guidance of $2.36-2.42 for the period, compared to the Thomson Reuters consensus estimate of $2.40. The company issued revenue guidance of $1.467-1.472 billion, compared to the consensus revenue estimate of $1.49 billion.Integra Lifesciences also updated its FY 2018 guidance to $2.36-2.42 EPS.

What price target have analysts set for IART?

13 Wall Street analysts have issued 1-year price objectives for Integra Lifesciences' shares. Their predictions range from $54.00 to $70.00. On average, they expect Integra Lifesciences' share price to reach $61.4167 in the next twelve months. This suggests a possible upside of 33.9% from the stock's current price. View Analyst Price Targets for Integra Lifesciences.

What is the consensus analysts' recommendation for Integra Lifesciences?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Integra Lifesciences in the last year. There are currently 1 sell rating, 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Integra Lifesciences.

What are Wall Street analysts saying about Integra Lifesciences stock?

Here are some recent quotes from research analysts about Integra Lifesciences stock:
  • 1. According to Zacks Investment Research, "Solid growth across all business segments has been the key growth catalyst for Integra LifeSciences. The company’s successful progress with its channel expansion strategy and Codman integration buoy optimism. Notably, the company announced plans within Orthopedics and Tissue Technologies segment to expand its sales channel, improve focus and competitiveness and better align the company’s product portfolio with clinical customers. Moreover, the strong investments in research and development is encouraging. However, the company’s reduced 2018 revenue guidance fails to instill confidence in the stock. Significant gross margin contractions caused by escalating costs have been a major headwind for the company in the last reported quarter. A tough competitive landscape adds to the woes. Integra LifeSciences has underperformed its industry over the past six months." (1/17/2019)
  • 2. BTIG Research analysts commented, "We hosted investor meetings with mgmt. of IART which included President & CEO for multiple days of meetings in the Midwest. Investors were interested in understanding a variety of topics, including the Codman integration, wound, nerve, and dural repair market dynamics, OTT channel changes, as well as other areas of the business. We came away with a clearer picture of IART’s progression toward a higher growth company driven by sales force productivity improvements, product registrations OUS, and a growing pipeline from Codman (a previously underfunded asset). The Street may not be as focused on much of the back-office work that has taken place at IART over FY18 but mgmt. was confident in their ability to meet FY18 organic revenue growth guidance (~5%) and grow above that in FY19 and beyond. Our incremental takeaways are below." (10/11/2018)

Has Integra Lifesciences been receiving favorable news coverage?

Media headlines about IART stock have been trending very positive this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Integra Lifesciences earned a daily sentiment score of 3.7 on InfoTrie's scale. They also assigned news articles about the life sciences company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days.

Are investors shorting Integra Lifesciences?

Integra Lifesciences saw a drop in short interest in December. As of December 14th, there was short interest totalling 1,680,975 shares, a drop of 26.9% from the November 30th total of 2,298,153 shares. Based on an average trading volume of 490,734 shares, the days-to-cover ratio is presently 3.4 days. Approximately 2.4% of the company's shares are sold short. View Integra Lifesciences' Current Options Chain.

Who are some of Integra Lifesciences' key competitors?

Who are Integra Lifesciences' key executives?

Integra Lifesciences' management team includes the folowing people:
  • Mr. Peter J. Arduini, Pres, CEO & Director (Age 54)
  • Dr. Richard E. Caruso Ph.D., Founder and Chairman Emeritus (Age 76)
  • Mr. Glenn G. Coleman, Corp. VP of International & CFO (Age 51)
  • Mr. Daniel L. Reuvers, Corp. VP and Pres of Specialty Surgical Solutions (Age 56)
  • Mr. Robert T. Davis Jr., Corp. VP and Pres of Orthopedics & Tissue Technologies (Age 60)

Who are Integra Lifesciences' major shareholders?

Integra Lifesciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Retirement Systems of Alabama (0.11%), First National Bank of Omaha (0.04%), Mitsubishi UFJ Asset Management UK Ltd. (0.04%), Louisiana State Employees Retirement System (0.02%), Cardinal Capital Management (0.02%) and Diversified Trust Co (0.02%). Company insiders that own Integra Lifesciences stock include Barbara B Hill, Christian S Schade, Daniel L Reuvers, Donald E Morel Jr, Glenn Coleman, James M Sullivan, Jeffrey Mosebrook, Joseph Vinhais, Keith Bradley, Richard D Gorelick, Richard E Caruso and Stuart Essig. View Institutional Ownership Trends for Integra Lifesciences.

Which institutional investors are selling Integra Lifesciences stock?

IART stock was sold by a variety of institutional investors in the last quarter, including First National Bank of Omaha, Oakbrook Investments LLC, Bank of Montreal Can and Louisiana State Employees Retirement System. Company insiders that have sold Integra Lifesciences company stock in the last year include Christian S Schade, Daniel L Reuvers, Glenn Coleman, Jeffrey Mosebrook, Joseph Vinhais, Keith Bradley, Richard E Caruso and Stuart Essig. View Insider Buying and Selling for Integra Lifesciences.

Which institutional investors are buying Integra Lifesciences stock?

IART stock was acquired by a variety of institutional investors in the last quarter, including Mitsubishi UFJ Asset Management UK Ltd., Cerebellum GP LLC, Campbell Newman Asset Management Inc., Diversified Trust Co, Legacy Financial Advisors Inc., Strs Ohio, Retirement Systems of Alabama and Cardinal Capital Management. Company insiders that have bought Integra Lifesciences stock in the last two years include Barbara B Hill and Donald E Morel Jr. View Insider Buying and Selling for Integra Lifesciences.

How do I buy shares of Integra Lifesciences?

Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Integra Lifesciences' stock price today?

One share of IART stock can currently be purchased for approximately $45.86.

How big of a company is Integra Lifesciences?

Integra Lifesciences has a market capitalization of $3.91 billion and generates $1.19 billion in revenue each year. The life sciences company earns $64.74 million in net income (profit) each year or $1.94 on an earnings per share basis. Integra Lifesciences employs 4,400 workers across the globe.

What is Integra Lifesciences' official website?

The official website for Integra Lifesciences is http://www.integralife.com.

How can I contact Integra Lifesciences?

Integra Lifesciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at 609-275-0500 or via email at [email protected]


MarketBeat Community Rating for Integra Lifesciences (NASDAQ IART)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  358 (Vote Outperform)
Underperform Votes:  402 (Vote Underperform)
Total Votes:  760
MarketBeat's community ratings are surveys of what our community members think about Integra Lifesciences and other stocks. Vote "Outperform" if you believe IART will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IART will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2019 by MarketBeat.com Staff

Featured Article: Current Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel